Final efficacy results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer (2015)
- Authors:
- Bell, Richard
- Brown, Julia
- Parmar, Mahesh
- Toi, Mark
- Suter, Thomas
- Steger, Guenther
- Pivot, Xavier
- Mackey, John
- Jackisch, Christian
- Dent, Rebecca
- Hall, Peter
- Mecke, Almut
- Morales, Leilani
- Provencher, Louise
- Staroslawska, Elzbieta
- Hegg, Roberto
- Vanlemmens, Laurence
- Kirsch, Andreas
- Schneeweiss, Andreas
- Masuda, Norikazu
- Overkamp, Friedrich
- Cameron, David
- Autor USP: HEGG, ROBERTO - FM
- Unidade: FM
- DOI: 10.1158/1538-7445.SABCS14-PD2-2
- Subjects: QUIMIOTERAPIA; NEOPLASIAS MAMÁRIAS (TERAPIA); ANTINEOPLÁSICOS
- Language: Inglês
- Imprenta:
- Source:
- Título: Cancer Research
- ISSN: 0008-5472
- Volume/Número/Paginação/Ano: v. 75, abst. PD2-2, May, 2015
- Conference titles: Annual CTRC-AACR San Antonio Breast Cancer Symposium
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
BELL, Richard et al. Final efficacy results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer. Cancer Research. Baltimore: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1158/1538-7445.SABCS14-PD2-2. Acesso em: 24 jan. 2026. , 2015 -
APA
Bell, R., Brown, J., Parmar, M., Toi, M., Suter, T., Steger, G., et al. (2015). Final efficacy results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer. Cancer Research. Baltimore: Faculdade de Medicina, Universidade de São Paulo. doi:10.1158/1538-7445.SABCS14-PD2-2 -
NLM
Bell R, Brown J, Parmar M, Toi M, Suter T, Steger G, Pivot X, Mackey J, Jackisch C, Dent R, Hall P, Mecke A, Morales L, Provencher L, Staroslawska E, Hegg R, Vanlemmens L, Kirsch A, Schneeweiss A, Masuda N, Overkamp F, Cameron D. Final efficacy results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer [Internet]. Cancer Research. 2015 ; 75[citado 2026 jan. 24 ] Available from: https://doi.org/10.1158/1538-7445.SABCS14-PD2-2 -
Vancouver
Bell R, Brown J, Parmar M, Toi M, Suter T, Steger G, Pivot X, Mackey J, Jackisch C, Dent R, Hall P, Mecke A, Morales L, Provencher L, Staroslawska E, Hegg R, Vanlemmens L, Kirsch A, Schneeweiss A, Masuda N, Overkamp F, Cameron D. Final efficacy results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer [Internet]. Cancer Research. 2015 ; 75[citado 2026 jan. 24 ] Available from: https://doi.org/10.1158/1538-7445.SABCS14-PD2-2 - Genetics of ramucirumab-associated hypertension in the ROSE/TRIO-012 breast cancer trial
- Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer
- Everolimus plus endocrine therapy for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer a clinical trial
- Bolero-4: A Phase 2, Open-Label, multicenter, single-arm trial investigating the efficacy and safety of first-line everolimus (EVE) in combination with letrozole (LET) in postmenopausal patients (PTS) with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2–) metastatic or locally advanced unresectable breast cancer (BC)
- Hormonioterapia neoadjuvante no câncer de mama
- Superexpressao do oncogene her-2/neu em carcinomas de mama: analise clinica e imunohistoquimica
- Tratamento neoadjuvante no câncer de mama
- Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)
- Terapia estrogenica e cancer de mama
- Efficacy and safety of Bevacizumab-Containing therapy in newly diagnosed ovarian cancer ROSiA Single-Arm Phase 3B Study
Informações sobre o DOI: 10.1158/1538-7445.SABCS14-PD2-2 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
